Embecta (EMBC) Research & Development (2020 - 2026)
Embecta (EMBC) posted Research & Development of $5.4 million for Q1 2026, up 17.39% sequentially from $4.6 million in Q4 2025, and down 32.5% YoY from $8.0 million in Q1 2025.
Embecta (EMBC) Research & Development (2020 - 2026) Analysis & Trends
Embecta has reported Research & Development for 7 years, with the latest figure at $5.4 million in Q1 2026.
- Quarterly Research & Development fell 32.5% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.0 million (down 72.26% YoY) and the FY2025 annual result came in at $37.3 million, down 52.66% from the prior year.
- Research & Development rose to $5.4 million in Q1 2026 per EMBC's latest filing, from $4.6 million in the prior quarter.
- Over five years, Research & Development peaked at $23.6 million in Q3 2023 and troughed at $4.4 million in Q2 2025.
- A 5-year average of $15.4 million and a median of $18.0 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2025: Research & Development soared 58.04% in 2023, then tumbled 78.43% in 2025.
- Over 5 years, Research & Development stood at $16.9 million in 2022, then grew by 19.53% to $20.2 million in 2023, then gained by 0.5% to $20.3 million in 2024, then slumped by 77.34% to $4.6 million in 2025, then gained by 17.39% to $5.4 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $5.4 million, $4.6 million, and $4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 132.89 Bn | 127.67 Bn | 1.96 Bn | 370.60 Mn |
| 2 | Becton Dickinson | 51.87 Bn | 51.01 Bn | 2.32 Bn | 258.00 Mn |
| 3 | Alcon | 35.51 Bn | 34.16 Bn | 1.68 Bn | 663.00 Mn |
| 4 | Resmed | 33.52 Bn | 32.06 Bn | 861.22 Mn | 105.73 Mn |
| 5 | Medline | 28.31 Bn | 25.63 Bn | 2.22 Bn | - |
| 6 | West Pharmaceutical Services | 24.97 Bn | 24.53 Bn | 329.20 Mn | 19.70 Mn |
| 7 | Solventum | 15.26 Bn | 14.86 Bn | 1.29 Bn | 178.00 Mn |
| 8 | Cooper Companies | 14.84 Bn | 14.70 Bn | 735.40 Mn | 42.50 Mn |
| 9 | Baxter International | 13.57 Bn | 11.42 Bn | 1.03 Bn | 129.00 Mn |
| 10 | Embecta | 313.45 Mn | 95.25 Mn | 153.30 Mn | 5.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.60 Mn |
| Mar 31, 2026 | 5.40 Mn |
| Dec 31, 2025 | 4.60 Mn |
| Sep 30, 2025 | 4.60 Mn |
| Jun 30, 2025 | 4.40 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Dec 31, 2024 | 20.30 Mn |
| Sep 30, 2024 | 19.80 Mn |
| Jun 30, 2024 | 20.40 Mn |
| Mar 31, 2024 | 18.40 Mn |
| Dec 31, 2023 | 20.20 Mn |
| Sep 30, 2023 | 23.60 Mn |
| Jun 30, 2023 | 22.60 Mn |
| Mar 31, 2023 | 22.10 Mn |
| Dec 31, 2022 | 16.90 Mn |
| Sep 30, 2022 | 17.90 Mn |
| Jun 30, 2022 | 14.30 Mn |
| Mar 31, 2022 | 18.00 Mn |
| Dec 31, 2021 | 16.70 Mn |
| Sep 30, 2021 | 19.50 Mn |